Literature DB >> 22799367

Serum miR-21 expression in human esophageal squamous cell carcinomas.

Er-Hui Cai1, Yong-Xin Gao, Zhong-zhi Wei, Wei-Ying Chen, Ping Yu, Ke Li.   

Abstract

To investigate the relationship between serum miRNA-21 (miR-21) expression in esophageal squamous cell carcinomas (ESCCs) and their clinicopathologic features, a 1:1 matched case-control study including 21 patients with ESCC and 21 age- and gender-matched healthy controls was carried out. Serum specimens were taken from all subjects. Total RNA was extracted and the stem-loop real time polymerase chain reaction was used to measure serum miR-21 in both groups. Clinical parameters were assessed to determine associations with serum miR-21 concentrations. Serum miR-21 expression in ESCC samples was significantly higher than in paired cancer-free samples (P <0.05). Metastasis was associated with mir-21 expression in serum (P <0.05), ESCC patients with metastasis having 8.4-fold higher serum miR-21 concentrations than healthy controls. There were no statistically significant associations between miR-21 expression and clinicopathologic parameters, such as gender (P >0.05), age (P >0.05), tumor location (P >0.05), cell differentiation (P >0.05), TNM staging (P >0.05), whether chemo/radiotherapy had been administered (P >0.05), or whether surgery had been performed (P >0.05). These findings suggest that the detection of microRNA-21 in serum might serve as a new tumor biomarker in diagnosis and assessment of prognosis of ESCCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22799367     DOI: 10.7314/apjcp.2012.13.4.1563

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  10 in total

1.  Plasma microRNAs to predict the response of radiotherapy in esophageal squamous cell carcinoma patients.

Authors:  Qi Yu; Bingxin Li; Ping Li; Zeliang Shi; Amanda Vaughn; Liucun Zhu; Shen Fu
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

2.  Serum miRNA expression in patients with esophageal squamous cell carcinoma.

Authors:  Beina Hui; Xin Chen; Lingyun Hui; Ruxing Xi; Xiaozhi Zhang
Journal:  Oncol Lett       Date:  2015-08-25       Impact factor: 2.967

3.  Bufalin induces apoptosis in human esophageal carcinoma ECA109 cells by inhibiting the activation of the mTOR/p70S6K pathway.

Authors:  Yan Ding; Wei Liu; Xiaoling Wang; Lingling Zhang; Meng Zhao; Huiyan Deng; Yueping Liu
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

4.  MicroRNA Expression in Plasma of Esophageal Squamous Cell Carcinoma Patients.

Authors:  Dong Hwahn Kahng; Gwang Ha Kim; Su Jin Park; Sora Kim; Moon Won Lee; Bong Eun Lee; Hoseok I
Journal:  J Korean Med Sci       Date:  2022-06-20       Impact factor: 5.354

5.  Differential expression of miR-21 and miR-75 in esophageal carcinoma patients and its clinical implication.

Authors:  Hongbo Lv; Zhanao He; Hongjiang Wang; Tongxin Du; Zuoliang Pang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

Review 6.  MicroRNAs as potential biomarkers in cancer: opportunities and challenges.

Authors:  Huiyin Lan; Haiqi Lu; Xian Wang; Hongchuan Jin
Journal:  Biomed Res Int       Date:  2015-03-22       Impact factor: 3.411

7.  NDAMDA: Network distance analysis for MiRNA-disease association prediction.

Authors:  Xing Chen; Le-Yi Wang; Li Huang
Journal:  J Cell Mol Med       Date:  2018-03-13       Impact factor: 5.310

8.  Long-Term Exercise Alters the Profiles of Circulating Micro-RNAs in the Plasma of Young Women.

Authors:  Fan Li; Muwei Bai; Jianfang Xu; Ling Zhu; Chengyi Liu; Rui Duan
Journal:  Front Physiol       Date:  2020-05-08       Impact factor: 4.566

Review 9.  miR-21: a non-specific biomarker of all maladies.

Authors:  Ana E Jenike; Marc K Halushka
Journal:  Biomark Res       Date:  2021-03-12

10.  A six-microRNA signature in plasma was identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma.

Authors:  Xin Zhou; Wei Wen; Jun Zhu; Zebo Huang; Lan Zhang; Huo Zhang; Lian-Wen Qi; Xia Shan; Tongshan Wang; Wenfang Cheng; Danxia Zhu; Yin Yin; Yan Chen; Wei Zhu; Yongqian Shu; Ping Liu
Journal:  Oncotarget       Date:  2017-05-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.